Every material Form 8-K Prestige Consumer Healthcare filed with the SEC in 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Prestige Consumer Healthcare reported fiscal second-quarter 2025 results for the three months ended September 30, 2024. Revenue fell 0.9% to $283.8 million, which the company attributed mainly to limited ability to supply strong demand for Clear Eyes and declines in the Cough & Cold and Analgesic categories, while diluted EPS rose to $1.09 from $1.07 and the company reaffirmed its full-year fiscal 2025 outlook. For shareholders, lower revenue was paired with slightly higher per-share earnings and unchanged guidance.
Q2 revenue of $283.8 million, down 0.9% from $286.3 million a year earlier
Q2 diluted EPS of $1.09 vs. $1.07; net income of $54.4 million vs. $53.6 million
First-half revenue of $550.9 million, down 2.6%; first-half diluted EPS of $2.06 (non-GAAP adjusted $1.98)
Fiscal 2025 outlook reaffirmed: revenue of $1,125 to $1,140 million and adjusted diluted EPS of $4.40 to $4.46
Prestige Consumer Healthcare reported fiscal first quarter 2025 results for the quarter ended June 30, 2024. Revenue fell 4.4% to $267.1 million and diluted EPS was $0.98, versus $1.06 a year earlier, while the company said results were ahead of its own expectations. The company reaffirmed its full-year fiscal 2025 outlook, so shareholders face lower year-over-year earnings with guidance unchanged.
Revenue of $267.1 million, down 4.4% from $279.3 million; organic revenue down 4.3%
Diluted EPS of $0.98 vs. $1.06 a year earlier; adjusted diluted EPS of $0.90
Operating cash flow of $54.8 million vs. $48.1 million; about 0.4 million shares repurchased for $26.0 million
Fiscal 2025 outlook reaffirmed: revenue of $1,125 million to $1,140 million; adjusted diluted EPS of $4.40 to $4.46
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Prestige Consumer Healthcare filing is on SEC EDGAR ↗. 8-K briefs of other companies →